Zobrazeno 1 - 10
of 91
pro vyhledávání: '"B. Tehard"'
Autor:
O Tredan, L Bensimon, M Apert, B Tehard, M Carita, A Khandelwal, J Gandhi, A Haiderali, M Huang, P Levy
Publikováno v:
Value in Health. 25:S54-S55
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1caff77361a27044748be69010add989
https://doi.org/10.1016/j.jval.2022.09.264
https://doi.org/10.1016/j.jval.2022.09.264
Publikováno v:
Value in Health. 25:S59-S60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca74753ea0692791af6c8a242fc346e0
https://doi.org/10.1016/j.jval.2022.09.289
https://doi.org/10.1016/j.jval.2022.09.289
Autor:
T Aparicio, C Mackosso, L Cagnan, L Bensimon, B Tehard, M Boussahoua, S Zhang, T Qu, Y Meng, E François
Publikováno v:
Value in Health. 25:S109
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::685f2dbb4cb5d689d10463ea11d10b57
https://doi.org/10.1016/j.jval.2022.09.531
https://doi.org/10.1016/j.jval.2022.09.531
Publikováno v:
Value in Health. 25:S124
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bd08b7327b2957e1d429cff83f2265e
https://doi.org/10.1016/j.jval.2022.09.601
https://doi.org/10.1016/j.jval.2022.09.601
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
BMC Cancer
BMC Cancer
Background Evidence from clinical trials suggests that the addition of bevacizumab to chemotherapy in the first-line treatment of patients with HER2-negative metastatic breast cancer improves progression-free survival (PFS) but not overall survival (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3304bc5108011c58f8e494e7bac7bfbc
http://link.springer.com/article/10.1186/s12885-019-5335-8
http://link.springer.com/article/10.1186/s12885-019-5335-8
Autor:
Alexandre Vainchtock, Julien Dupin, M. Laurent, V. Machuron, R. Ghorbal, B Tehard, M. Gilberg, M. Prodel
Publikováno v:
Value in Health. 23:S471-S472
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d101f1cb27637b778c128bae7c2ca4e
https://doi.org/10.1016/j.jval.2020.08.414
https://doi.org/10.1016/j.jval.2020.08.414
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 23(8)
Objective France has included health economic assessment (HEA) as an official criterion for innovative drug pricing since 2013. Until now, no cost-effectiveness threshold (CET) has been officially proposed to qualify incremental cost-effectiveness ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55270b096aeb68b3e8475512aaadb5d5
https://pubmed.ncbi.nlm.nih.gov/32828226
https://pubmed.ncbi.nlm.nih.gov/32828226
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 1, p e0226196 (2020)
PLoS ONE, Vol 15, Iss 1, p e0226196 (2020)
The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting. This study used a partitioned survival model, with three discre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1dd95c7d483bff64b6b4ac3349da175
https://pubmed.ncbi.nlm.nih.gov/31945065
https://pubmed.ncbi.nlm.nih.gov/31945065
Autor:
C. Chamielec, G. de Pouvourville, Julie Chevalier, Isabelle Borget, Bruno Detournay, B Tehard, P. Levy, Stéphane Roze
Publikováno v:
Value in Health. 23:S646
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45d0b9b51244317cc559131036e49061
https://doi.org/10.1016/j.jval.2020.08.1459
https://doi.org/10.1016/j.jval.2020.08.1459
Publikováno v:
Value in Health. 23:S648
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb82ae16636b4b760da87c9ce24a275b
https://doi.org/10.1016/j.jval.2020.08.1473
https://doi.org/10.1016/j.jval.2020.08.1473